Ihre Suche nach:
25 Ergebnis(se) in 0.10 s
-
DUKAS_118629658_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629666_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629659_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629679_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured playing on his drum set.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629681_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured playing on his drum set.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629667_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629668_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629664_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629662_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629665_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629672_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with mum Kristina Gray and pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629661_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629660_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629663_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629675_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629670_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629669_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629671_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629677_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629678_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629680_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629676_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629674_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629673_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved. -
DUKAS_118629682_EYE
‘There is a fear that this will eradicate dwarfism’: the controversy over a new growth drug
ÔThere is a fear that this will eradicate dwarfismÕ: the controversy over a new growth drug. A new treatment could help children with achondroplasia, the most common form of dwarfism, grow taller and avoid health problems in later life. But there are concerns about whether this is ethical. Pictured is 9 year old Samuel Gray at home in Rugby who is taking part in a Biomarin research drug trial for achondroplasia - vorsitide phase 3.
Sanuel is pictured with pet dog Hamish.
Photo by Fabio De Paola** Clearance required prior to publication**
© Fabio De Paola / Guardian / eyevine
Contact eyevine for more information about using this image:
T: +44 (0) 20 8709 8709
E: info@eyevine.com
http://www.eyevine.com
(FOTO: DUKAS/EYEVINE)
© Guardian / eyevine. All Rights Reserved.